everyone, clinical continue enable TriSalus to expanding trajectory. quarter track morning, we report footprint, XX% advancements, growth us key you drive today. I'm joining this Good the sustained that our and for growth strategic has for With initiatives we're thank pleased upward future. us the and that foreseeable continue of on innovative to execute market to of that annually to a and product will launches delivered strong
of compared of reimbursement, TriSalus $X.X in key driven QX, For account specific treating a this education XXXX. within accounts, clinical around growth: TriNav the supporting activations, factors data continued period to patients. XX% permanent our Several have existing new compelling reported use in reflecting million, penetration same deeper and total the a revenue complex growth TriNav
personnel of the side, year, commercial expect mix the a end high-volume we been XX TriSalus By steadily has markets. expanding have of On the commercial clinical via specialists. all its footprint sales across to and approximately
growth coming I'll over Murphy, for our markets. review Financial expansion to our Our a call is the comprehensive procedure the to our central establish results to years. annual in XX% Chief call. goal financial confidence later This the of Sean Officer, coverage in high of detailed turn sustaining is over
radiology communities interventional hospital strong. commitment and the remain engaging to Our
of especially share growing technology, complex patient of targeted value our tumors, to We cases. clinical in evidence, the continue to therapy body PEDD more showcasing the delivering
that clinical our I the for we're use year-end, to registry launch of initiation attention HEOR be This year the end want substantiating of published to draw my Large, analysis discussed by the and of of in important will in multinodular the we year, TriNav further of catalysts trial complex efficacy The the PROTECT launch an treating TriNav outcome, goiter data on. TriNav focused As approach in in your later new key comprehensive of TriNav with half the the additional to highlights includes of patients. opening remarks. be XXXX first
positive and trial half of in TriNav X.X uveal data to patients XX clinical melanoma discussions, I XXXX, lastly, summary EBITDA steps goal next with cash to completion data liver in reduction become of of in half in the and the partnership XXXX. in significant with first and XXXX. Phase enrolled launch final the second metastasis our of initiation PERIO-XX, determined burn And expenses in
extends the me of approaches. for to product challenges signifies our underway let the portfolio interventional solutions all and launches. to drug the and going launch We're with excited addressing of full that begin our is Catheter TriNav delivery of complex TriNav offer So Large and pressure-enabled This treatment product suite to commitment embolization TriGuide the patients radiologists well. announce launch
subsegmental provides embolization radio and require device to full procedures diameter millimeters lobar diameters million of and TriNav chemo X.X market. for significant which $XXX and vessel current the The access addresses number are to up segmental A cases larger approaches. device,
trackability feedback anatomy, market utilization. an months complex we evaluation its highly Before response, tumor complications and vascular received navigating performance, launch, in on reduced and conducted over resource X improved extensive favorable
enhanced enhanced designed its This and providing clinicians technology, of procedures. outcomes. XXXX, accuracy With precise on in aims elevate and abilities TriNav efficiency, to builds advanced X.X navigation the patient supporting X.X version our next-generation further track placement. we improved during to optimized trackability, original offer on TriNav are more the Additionally, with procedural to tracking half device TriNav for launch second control
We designed In safety program. through A a complex steering demonstrate will parallel, enhanced of improved potential and with combination is clinical explore the normal our enhance efficacy studies, will our efficacy the demonstrate mechanisms this we using tissue TriNav commercial trans-arterial in impact of delivery system, PEDD these investigator-initiated and delivered impact radio investigate new innovative the of TriNav to across chemo underscoring bland, product when through the with cancers. resistant broad of advancing difficult-to-treat in spectrum efforts, to will and highlight theme difficult-to-treat to expect of the enhanced program and be via therapies This which we're completions. patients central safety further technology. system DELIVER program aim the and embolization therapeutic to approaches overcome
tumors multiple complex size; define of multifocal, tumor or therapy, liver greater dysfunction; This centimeters X embolization and bilobar We and have which diffuse lesions. these following: patients previous involving blood large means comorbidities, though poor hypovascular is significant X in as than more the liver supply. tumors, including burden; or they
Sarasota Ralph of sites side enroll call, effects reduced leading multinodular demonstrate Hospital. by study, target for stands Pressure XXX which been Tufano goal on lower The Dr. versus TriNav Juan to to patient Enabled Retrograde treatment goiters. academic of Thyroid Disease, I has General efficacy, The introduced initiated enhanced Embolization Dr. using a surgery. Control X patients Therapy PROTECT last Camacho and new quarter's for Occlusive population across Now and to with is at treat cost
is goiter with nodule. the common at X% found approximately quite Multinodular adult of population
the million. expands age potential by approximately We for in TriNav market market opportunity Some XX. of this addressable the publications an XX,XXX report incremental procedures, representing a individuals $XXX up procedure XX% prevalence estimate that of of over to
for to focusing billion. our is addition markets, In pancreatic in the liver on over now $X embolization market technologies opportunity
Additionally, TriNav the allowing into new reimbursement procedure eligible for seamless this practices. integration current HCPCS utilizing for code, same is billing
of to patients hypoparathyroidism, pressure, nodule. with dysphagia, Ablation include is laryngeal due choking restricted treatment bleeding. nodules these also used, recurrent the and to numerous Risks nerve are injury hypothyroidism, obstruction. symptoms airway surgery Today, sensation but of typically referred more or of thyroidectomy extensive single to
invasive, several benefits to it patient since injection uses injury has the minimal minimally is particles embolization with thyroid to to the of allows significant have TriNav and create ischemic downtime. Bland nodule, and an
studies the technology intend additional to all of complex the first half TriNav patient also aimed open other in DELIVER in of XXXX, We at types. elucidating benefits
them potential information We are program's patients. clinical DELIVER enthusiastic their confidently about provide for the the unique benefits need technology's highlight and to select physicians to our
we to conventional XXXX catheters Additionally, to complications XXXX clinical the both another compared an year to our at safety data, TriNav as period. data over time to real-world and in update capturing forward of looking HEOR study providing look for
This updated XXX into PEDD study data PEDD characteristics all controlled accumulate valuable years utilization technology set have which otherwise that million benefits additional like covering from alternative complication payers. patients clinical These with year through adds clinical to of TriNav trials. patients, in an rates of non-PEDD would key XXX compared U.S. data, of of a taken approaches, XX% those insights the large provides randomized of XX,XXX many example, for patient
Key overall to due -- reduced tumor. fluid inpatient had costs post-procedural of reduced patient have the which findings a rates overall health TriNav due significantly abdomen complications, number complications. of reduced clinical from drain time the function, delivered chemotherapeutic to and amount means paracentesis, included reduced stays, their care reduced times XX-day to increase of failing the the following: liver
is adoption its and in the community their the engaging of algorithms. U.S., oncologists medical applications to continue on treatment The its to educate understanding value therapeutic As PEDD commercial we expand PEDD different of tumors toxicity. into we to and discuss the and the medical with embolization interested reduced delivery of integrating also in enhanced endocrinologists are value them benefits use in
Now me let to turn nelitolimod.
uveal at Society SITC. results immuno-oncology This use of Immunotherapy clinical from delivery, pressure-enabled liver melanoma or metastases. investigated of trial PEDD, We pressure-enabled Phase trial the meeting, of PERIO-XX presented nelitolimod I of drug the regional the Cancer in
to in study included modulate uveal of immune shown has nelitolimod cells, patients. a Phase escalation administration could dose melanoma was I arterial that cohorts myeloid liver X Nelitolimod suggesting total been PEDD efficacy a of in enhance XX favorably and hepatic metastases inhibitors. The studies for the trial of checkpoint preclinical
B, received treated, of was and A, greater patients nivo, primary and burden a received significant and prior plus The survival X-centimeter lesions in ipi. XX which as in than which nelitolimod patients. XX% the had therapy of systemic of XX tumor has number Cohort the C nivo and progression-free the patients, XX% monotherapy. XX% overall substantial XX lesions liver survival. a Cohort plus of was were nelitolimod XX and nelitolimod patients endpoints cohort patients, received
milligrams in Key XX.X%, was adverse Cohort involved. was treatment-related inhibitor ipi/nivo, The nelitolimod II was the findings that was dose events, and X-year X XX% median OS The and where median XX.X and The was Phase patients. recommended or OS months. was of was most Grade included PFS which administration checkpoint in months. X.X X/X of frequently C, occurred patients X-year the XX XX.X%, plus OS nivo
Disease was checkpoint which XX%. in with was not restriction the control at in X was survival and patients XX%, PFS was checkpoint the refractory, refractory status. were patients. similar dependent on naive patients outcomes rate and outcomes checkpoint-naive the checkpoint HLA in survival similar with The the XX%, the OS XX overall
durable PEDD ctDNA, IL-XX valuable with correlated provides heavily in survival circulating administrated clinical uveal levels. The the pretreated and with HLA and tumor increased benefits patients, Among combined of checkpoint, was MDSCs IL-XX tumor status. XX%, metastases that DNA, melanoma and and suggest clearance promising regardless of benefit reduced clinical nelitolimod, patients with liver results
a are liver. substantiate pretreated has nelitolimod impact the with checkpoint administered create liver to can amplify therapeutic immune of results the microenvironment potential encouraged of more by melanoma particularly findings via suggest heavily uveal that metastases. hypothesis the for inhibitors, PEDD tumor that favorable We nelitolimod our in patients highly the These which PERIO-XX,
partnerships challenging unlock high challenging clinical melanoma actively in access liver like-minded drive exploring patient we're the potential metastasis, this its population strategic end, this committed can Given this further. reach. to expanding to partnerships therapeutic and with approach. organizations, with we and this can indication To of commitment collaborating unmet we are by in underscores the broaden believe indication. deeply this need to to prognosis exploring advance this The that accelerate that We associated innovative our program impactful advancements therapy uveal
study Regarding our with profile. a involves I evaluates immune both and the responses. nelitolimod's PEDD, pancreatic approach safety device, that strong includes where tumor retrograde PERIO-XX, systemic infusion This a promote nelitolimod to ability novel tumor innovative and demonstrated delivery favorable delivery microenvironment venous it via study pancreatic of Phase a performance modulate clinical
The least targeted To failed X events related XX dose date, potentially are the This disease or levels. population signal. line therapeutic completed we favorable have deliver well who conditions. is enrollment has with in infusions locally to have no to intratumoral breakthrough pancreas, the PEDD technology precision pancreatic and and and pancreas target was safety agents therapy. at advanced devices standard of to treatment designed nelitolimod for efficacy X directly with of and systemic patients patients PEDD potentially their safety severe procedure, immune There with been the been tolerated enhancing evaluating
further the we'll outline about enthusiastic indicate novel We're approaches. technology. steps. next via safety bit monotherapy the findings infusion with nelitolimod potential These regionally PEDD the exploration of pancreatic combined data using our combinatorial delivered final And our of mid-XXXX, nelitolimod once support of emerges
experience on MDSCs is over support immune with of well particular, liver that in on be clinical has for effects metastatic nelitolimod liver to patients. beneficial with tolerated and our in XX macrophages nelitolimod these tumors, these ability favorable may outcomes. In may in patients MX and drug primary clinical treating metastases effects favorable and mediate the Based patients this and
importantly, value clinical for nelitolimod steps be positive, next efforts exploring evolution, Phase clinical on several which locally liver in advanced uveal focused positioning trials, in to approach After us our Most EBITDA represents sustainability and drive this and long-term metastases our pancreatic focused we a melanoma milestone pivotal have will cancer. determining I partnering company's creation.
TriNav milestone of remaining in discipline. company focus in becoming accelerating a driving We're of our growth supported revenue XXXX, significant adoption positive XXXX, includes to on that embolization, sales and complete team TriNav this interventional strategy chemo and committed performance, our while targeting provide Large, solution growth in EBITDA to of achieve sales a market by operational launching XX% To will and optimizing X.X a TriNav penetration radiologists. robust expanding to radio
shareholders. efforts we're Additionally, teams, long-term our aligning profitability. and measures operations we'll operational improve and to for milestone the margins, product cost that hitting every this and in contributes streamline to implement dollar By confident control of creating value sales ensuring
objective line with on Before to strengthen I our turn the call I'll company's pleased over in by close We remain pipeline our against top the Sean, performance revenue operational our XX% execute over we're company to building and and to achieve confident foundation. growth, track our strategy. our ability saying advance
provide I'll an performance to Sean the over quarter. to turn Murphy in on update With financial it our that,
